Arrowhead Research reported $983.69M in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Agios Pharmaceuticals USD 31.17M 4.57M Jun/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 983.69M 5.77M Jun/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
Ligand Pharmaceuticals USD 1.13B 679.48M Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Moderna USD 1.29B 11M Jun/2026
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 49.01B 2.02B Jun/2026
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
TG Therapeutics USD 754.37M 68K Sep/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026
Xencor USD 170.11M 5.06M Jun/2026